Global Diabetic Nephropathy 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI11243352

Publication Date:

November 29, 2024

Pages:

106

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Diabetic Nephropathy market size was valued at US$ 2393.5 million in 2023. With growing demand in downstream market, the Diabetic Nephropathy is forecast to a readjusted size of US$ 3363.3 million by 2030 with a CAGR of 5.0% during review period.
The research report highlights the growth potential of the global Diabetic Nephropathy market. Diabetic Nephropathy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Diabetic Nephropathy. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Diabetic Nephropathy market.
Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents鈥� wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Key Features:
The report on Diabetic Nephropathy market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Diabetic Nephropathy market. It may include historical data, market segmentation by Type (e.g., ACE Inhibitors, ARBs), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Diabetic Nephropathy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Diabetic Nephropathy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Diabetic Nephropathy industry. This include advancements in Diabetic Nephropathy technology, Diabetic Nephropathy new entrants, Diabetic Nephropathy new investment, and other innovations that are shaping the future of Diabetic Nephropathy.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Diabetic Nephropathy market. It includes factors influencing customer ' purchasing decisions, preferences for Diabetic Nephropathy product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Diabetic Nephropathy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Diabetic Nephropathy market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Diabetic Nephropathy market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Diabetic Nephropathy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Diabetic Nephropathy market.
麻豆原创 Segmentation:
Diabetic Nephropathy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
ACE Inhibitors
ARBs
Diuretics
Calcium Channel Blockers(CCBs)
Renin Inhibitors
Connective Tissue Growth Factor (CTGF) Inhibitors
Antioxidant Inflammation Modulators(AIMs)
Monocyte Chemoattractant Protein (MCP)Inhibitors
Endothelin-A Receptor(ETAR)Antagonist
G Protein-Coupled Receptors (GPCRs)
Segmentation by application
Hospitals
Cancer Research Institutes
Diagnostic Labs
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Merck
Pfizer
Abbott Laboratories
Sanofi
Eli Lilly
AbbVie
Reata Pharmaceuticals
Bayer
Mitsubishi Tanabe Pharma

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Diabetic Nephropathy 麻豆原创 Size 2019-2030
2.1.2 Diabetic Nephropathy 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Diabetic Nephropathy Segment by Type
2.2.1 ACE Inhibitors
2.2.2 ARBs
2.2.3 Diuretics
2.2.4 Calcium Channel Blockers(CCBs)
2.2.5 Renin Inhibitors
2.2.6 Connective Tissue Growth Factor (CTGF) Inhibitors
2.2.7 Antioxidant Inflammation Modulators(AIMs)
2.2.8 Monocyte Chemoattractant Protein (MCP)Inhibitors
2.2.9 Endothelin-A Receptor(ETAR)Antagonist
2.2.10 G Protein-Coupled Receptors (GPCRs)
2.3 Diabetic Nephropathy 麻豆原创 Size by Type
2.3.1 Diabetic Nephropathy 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Diabetic Nephropathy 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Diabetic Nephropathy Segment by Application
2.4.1 Hospitals
2.4.2 Cancer Research Institutes
2.4.3 Diagnostic Labs
2.5 Diabetic Nephropathy 麻豆原创 Size by Application
2.5.1 Diabetic Nephropathy 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Diabetic Nephropathy 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Diabetic Nephropathy 麻豆原创 Size by Player
3.1 Diabetic Nephropathy 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Diabetic Nephropathy Revenue by Players (2019-2024)
3.1.2 Global Diabetic Nephropathy Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Diabetic Nephropathy Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Diabetic Nephropathy by Regions
4.1 Diabetic Nephropathy 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Diabetic Nephropathy 麻豆原创 Size Growth (2019-2024)
4.3 APAC Diabetic Nephropathy 麻豆原创 Size Growth (2019-2024)
4.4 Europe Diabetic Nephropathy 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Diabetic Nephropathy 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Diabetic Nephropathy 麻豆原创 Size by Country (2019-2024)
5.2 Americas Diabetic Nephropathy 麻豆原创 Size by Type (2019-2024)
5.3 Americas Diabetic Nephropathy 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Diabetic Nephropathy 麻豆原创 Size by Region (2019-2024)
6.2 APAC Diabetic Nephropathy 麻豆原创 Size by Type (2019-2024)
6.3 APAC Diabetic Nephropathy 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Diabetic Nephropathy by Country (2019-2024)
7.2 Europe Diabetic Nephropathy 麻豆原创 Size by Type (2019-2024)
7.3 Europe Diabetic Nephropathy 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Diabetic Nephropathy by Region (2019-2024)
8.2 Middle East & Africa Diabetic Nephropathy 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Diabetic Nephropathy 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Diabetic Nephropathy 麻豆原创 Forecast
10.1 Global Diabetic Nephropathy Forecast by Regions (2025-2030)
10.1.1 Global Diabetic Nephropathy Forecast by Regions (2025-2030)
10.1.2 Americas Diabetic Nephropathy Forecast
10.1.3 APAC Diabetic Nephropathy Forecast
10.1.4 Europe Diabetic Nephropathy Forecast
10.1.5 Middle East & Africa Diabetic Nephropathy Forecast
10.2 Americas Diabetic Nephropathy Forecast by Country (2025-2030)
10.2.1 United States Diabetic Nephropathy 麻豆原创 Forecast
10.2.2 Canada Diabetic Nephropathy 麻豆原创 Forecast
10.2.3 Mexico Diabetic Nephropathy 麻豆原创 Forecast
10.2.4 Brazil Diabetic Nephropathy 麻豆原创 Forecast
10.3 APAC Diabetic Nephropathy Forecast by Region (2025-2030)
10.3.1 China Diabetic Nephropathy 麻豆原创 Forecast
10.3.2 Japan Diabetic Nephropathy 麻豆原创 Forecast
10.3.3 Korea Diabetic Nephropathy 麻豆原创 Forecast
10.3.4 Southeast Asia Diabetic Nephropathy 麻豆原创 Forecast
10.3.5 India Diabetic Nephropathy 麻豆原创 Forecast
10.3.6 Australia Diabetic Nephropathy 麻豆原创 Forecast
10.4 Europe Diabetic Nephropathy Forecast by Country (2025-2030)
10.4.1 Germany Diabetic Nephropathy 麻豆原创 Forecast
10.4.2 France Diabetic Nephropathy 麻豆原创 Forecast
10.4.3 UK Diabetic Nephropathy 麻豆原创 Forecast
10.4.4 Italy Diabetic Nephropathy 麻豆原创 Forecast
10.4.5 Russia Diabetic Nephropathy 麻豆原创 Forecast
10.5 Middle East & Africa Diabetic Nephropathy Forecast by Region (2025-2030)
10.5.1 Egypt Diabetic Nephropathy 麻豆原创 Forecast
10.5.2 South Africa Diabetic Nephropathy 麻豆原创 Forecast
10.5.3 Israel Diabetic Nephropathy 麻豆原创 Forecast
10.5.4 Turkey Diabetic Nephropathy 麻豆原创 Forecast
10.5.5 GCC Countries Diabetic Nephropathy 麻豆原创 Forecast
10.6 Global Diabetic Nephropathy Forecast by Type (2025-2030)
10.7 Global Diabetic Nephropathy Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Diabetic Nephropathy Product Offered
11.1.3 Novartis Diabetic Nephropathy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Diabetic Nephropathy Product Offered
11.2.3 Merck Diabetic Nephropathy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Merck Main Business Overview
11.2.5 Merck Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Diabetic Nephropathy Product Offered
11.3.3 Pfizer Diabetic Nephropathy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Information
11.4.2 Abbott Laboratories Diabetic Nephropathy Product Offered
11.4.3 Abbott Laboratories Diabetic Nephropathy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Abbott Laboratories Main Business Overview
11.4.5 Abbott Laboratories Latest Developments
11.5 Sanofi
11.5.1 Sanofi Company Information
11.5.2 Sanofi Diabetic Nephropathy Product Offered
11.5.3 Sanofi Diabetic Nephropathy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Sanofi Main Business Overview
11.5.5 Sanofi Latest Developments
11.6 Eli Lilly
11.6.1 Eli Lilly Company Information
11.6.2 Eli Lilly Diabetic Nephropathy Product Offered
11.6.3 Eli Lilly Diabetic Nephropathy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Eli Lilly Main Business Overview
11.6.5 Eli Lilly Latest Developments
11.7 AbbVie
11.7.1 AbbVie Company Information
11.7.2 AbbVie Diabetic Nephropathy Product Offered
11.7.3 AbbVie Diabetic Nephropathy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 AbbVie Main Business Overview
11.7.5 AbbVie Latest Developments
11.8 Reata Pharmaceuticals
11.8.1 Reata Pharmaceuticals Company Information
11.8.2 Reata Pharmaceuticals Diabetic Nephropathy Product Offered
11.8.3 Reata Pharmaceuticals Diabetic Nephropathy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Reata Pharmaceuticals Main Business Overview
11.8.5 Reata Pharmaceuticals Latest Developments
11.9 Bayer
11.9.1 Bayer Company Information
11.9.2 Bayer Diabetic Nephropathy Product Offered
11.9.3 Bayer Diabetic Nephropathy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Bayer Main Business Overview
11.9.5 Bayer Latest Developments
11.10 Mitsubishi Tanabe Pharma
11.10.1 Mitsubishi Tanabe Pharma Company Information
11.10.2 Mitsubishi Tanabe Pharma Diabetic Nephropathy Product Offered
11.10.3 Mitsubishi Tanabe Pharma Diabetic Nephropathy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Mitsubishi Tanabe Pharma Main Business Overview
11.10.5 Mitsubishi Tanabe Pharma Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.